[Therapeutic strategy for patients with stable-stage chronic kidney failure].
Takamitsu
Yoshihiro
Y
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D018753:Diet, Protein-Restricted; D018450:Disease Progression; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D007211:Indoles / Q000627:therapeutic use; D007564:Japan / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D019808:Losartan / Q000627:therapeutic use; D006435:Renal Dialysis / Q000706:statistics & numerical data
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007211:Indoles; C052035:trandolapril; D019808:Losartan